| (Values in U.S. Thousands) | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 |
| Sales | 80 | 80 | 0 | -10 | 80 |
| Sales Growth | unch | unch | +100.00% | -112.50% | unch |
| Net Income | -680 | -720 | -900 | 190 | -370 |
| Net Income Growth | +5.56% | +20.00% | -573.68% | +151.35% | +31.48% |
Appili Therapeutics Inc (APLIF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Appili Therapeutics Inc. is a biopharmaceutical company. It acquires, develops and commercializes novel medicines for unmet needs in the infectious disease. The company's lead product consist ATI-2307, ATI-1501 and ATI-1701 which are in clinical stage. Appili Therapeutics Inc. is based in Halifax, Canada.
Fiscal Year End Date: 03/31